Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation

被引:73
作者
Sampath, Deepa [1 ]
Calin, George A. [1 ]
Puduvalli, Vinay K. [2 ]
Gopisetty, Gopal [2 ]
Taccioli, Cristian [3 ]
Liu, Chang-Gong [1 ]
Ewald, Brett [1 ]
Liu, Chaomei [1 ]
Keating, Michael J. [4 ]
Plunkett, William [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[3] Ohio State Univ, Coll Med, Ctr Comprehens Canc, Columbus, OH 43210 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; HEMATOLOGIC MALIGNANCIES; DNA-DAMAGE; CANCER; P53; EXPRESSION; PROTEIN; GENOME; CLL;
D O I
10.1182/blood-2008-09-178707
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic lymphocytic leukemia (CLL) is characterized by cells that exhibit dysfunctional apoptosis. Here, we show that deacetylase inhibition led to the E2F1- and myc-mediated transcriptional activation of the microRNA miR106b in primary CLL cells. Induction of miR106b was associated with a down-regulation in the levels of the E3-ubiquitin ligase Itch. Decreases in Itch protein levels were associated with a reciprocal accumulation of its proapoptotic substrate, TAp73 (p73), and induction of p53 up-regulated modulator of apoptosis (PUMA) mRNA and protein. This event was accompanied by mitochondrial dysfunction, processing of caspase-9, and apoptosis of CLL cells. Ectopic expression of miR106b in CLL cells demonstrated that Itch was a direct target of miR106b such that miR106b-induced decreases in Itch resulted in an accumulation of p73. Thus, our results identify a novel regulatory mechanism wherein microRNA regulate cell survival by mediating the posttranscriptional down-regulation of an ubiquitin ligase, leading to the induction of a proapoptotic regulator in malignant cells. Silencing of miRNA expression in CLL may selectively suppress proapoptotic pathways, providing such tumors with a survival advantage. Consequently, chemotherapeutic drugs that activate miR106b could initiate a p53-independent mechanism that targets CLL cells. (Blood. 2009; 113: 3744-3753)
引用
收藏
页码:3744 / 3753
页数:10
相关论文
共 43 条
[1]   MicroRNAs and other tiny endogenous RNAs in C-elegans [J].
Ambros, V ;
Lee, RC ;
Lavanway, A ;
Williams, PT ;
Jewell, D .
CURRENT BIOLOGY, 2003, 13 (10) :807-818
[2]   The microRNA.org resource: targets and expression [J].
Betel, Doron ;
Wilson, Manda ;
Gabow, Aaron ;
Marks, Debora S. ;
Sander, Chris .
NUCLEIC ACIDS RESEARCH, 2008, 36 :D149-D153
[3]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[4]   A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia [J].
Byrd, JC ;
Marcucci, G ;
Parthun, MR ;
Xiao, JJ ;
Klisovic, RB ;
Moran, M ;
Lin, TS ;
Liu, SJ ;
Sklenar, AR ;
Davis, ME ;
Lucas, DM ;
Fischer, B ;
Shank, R ;
Tejaswi, SL ;
Binkley, P ;
Wright, J ;
Chan, KK ;
Grever, MR .
BLOOD, 2005, 105 (03) :959-967
[5]   Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia [J].
Carter, A ;
Lin, K ;
Sherrington, PD ;
Atherton, M ;
Pearson, K ;
Douglas, A ;
Burford, A ;
Brito-Babapulle, V ;
Matutes, E ;
Catovsky, D ;
Pettitt, AR .
LEUKEMIA, 2006, 20 (04) :737-740
[6]   Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia [J].
Cobo, F ;
Martínez, A ;
Pinyol, M ;
Hernández, L ;
Gómez, M ;
Beá, S ;
Esteve, J ;
Rozman, M ;
Bosch, F ;
López-Guillermo, A ;
Montserrat, E ;
Campo, E .
LEUKEMIA, 2002, 16 (06) :1028-1034
[7]   DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes [J].
Costanzo, A ;
Merlo, P ;
Pediconi, N ;
Fulco, M ;
Sartorelli, V ;
Cole, PA ;
Fontemaggi, G ;
Fanciulli, M ;
Schiltz, L ;
Blandino, G ;
Balsano, C ;
Levrero, M .
MOLECULAR CELL, 2002, 9 (01) :175-186
[8]   Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells [J].
Dai, Yun ;
Chen, Shuang ;
Kramer, Lora B. ;
Funk, Vanessa L. ;
Dent, Paul ;
Grant, Steven .
CLINICAL CANCER RESEARCH, 2008, 14 (02) :549-558
[9]   P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS [J].
DOHNER, H ;
FISCHER, K ;
BENTZ, M ;
HANSEN, K ;
BENNER, A ;
CABOT, G ;
DIEHL, D ;
SCHLENK, R ;
COY, J ;
STILGENBAUER, S ;
VOLKMANN, M ;
GALLE, PR ;
POUSTKA, A ;
HUNSTEIN, W ;
LICHTER, P .
BLOOD, 1995, 85 (06) :1580-1589
[10]   Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL) [J].
Duvic, Madeleine ;
Talpur, Rakshandra ;
Ni, Xiao ;
Zhang, Chunlei ;
Hazarika, Parul ;
Kelly, Cecilia ;
Chiao, Judy H. ;
Reilly, John F. ;
Ricker, Justin L. ;
Richon, Victoria M. ;
Frankel, Stanley R. .
BLOOD, 2007, 109 (01) :31-39